Moleculin Biotech raises $6.0M via warrant exercise; issues 64.9M new warrants at $0.55

Moleculin Biotech, Inc.

Gross proceeds of $6.0M from immediate cash exercise of 16.2M existing warrants at $0.37/share.
Issues new unregistered Series F warrants to purchase up to 64.9M shares at $0.55, exercisable upon shareholder approval.
New warrants have 5-year term, anti-dilution protection with a floor of $0.11, and a 4.99%/9.99% beneficial ownership cap.
Company to file resale registration statement by Sep 26, 2025; use proceeds for working capital.
Transaction closed Aug 28, 2025; Roth Capital Partners acted as financial advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.